Percheron Therapeutics (AU:PER) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Percheron Therapeutics has successfully completed its Share Purchase Plan, raising $1.85 million from 201 applications, allowing retail shareholders to invest on the same terms as institutions. This follows a two-tranche placement raising $13 million, positioning the company to further its initiatives and await key clinical trial data next month. The funds will support ongoing development of therapies for rare diseases, including their promising treatment for Duchenne Muscular Dystrophy.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.